|
Match
|
Document |
Document Title |
|
|
4774087 |
Micro-size fibrinolytic plasmin
Microplasmin and microplasminogen are plasmin and plasminogen derivatives produced by the action of plasmin non plasmin/plasminogen at high pH. The action of plasmin at this pH cleaves the heavy...
|
|
|
4772585 |
Protein thrombolytic agent with absorption enhancing agent
The absorption rate of protein-thrombolytic agents with medicinal properties in the blood is enhanced by administering the protein intramuscularly together with an absorption enhancing agent, e.g....
|
|
|
4755383 |
Pharmaceutical composition suitable for intestinal administration
A pharmaceutical composition is disclosed which comprises a physiologically active substance possessing peptide bonds in its structure and being inactivable by digestive enzymes, the active...
|
|
|
4752581 |
Novel compounds
A fibrinolytically active hybrid protein which comprises one chain of a 2-chain protease linked to a chain of a different 2-chain protease, or to the same chain of the same protease, at least one...
|
|
|
4752466 |
Thrombin aerosol
A process is disclosed for delivery thrombin in dry powdered form from an aerosol container by first lyophilizing an aqueous solution of thrombin and a thrombin-compatible synthetic polymer e.g....
|
|
|
4752603 |
Plasminogen activator and pharmaceutical composition having thrombolytic activity
A new plasminogen activator which is very similar to the plasminogen activator from blood can be isolated in good amounts from the culture fluid of human melanoma cells. This new plasminogen...
|
|
|
4741903 |
Novel enzyne derivatives
A derivative of a fibrinolytic enzyme in which the catalytic site on the enzyme which is responsible for fibrinolytic activity is blocked by a human protein attached thereto by way of a reversible...
|
|
|
4741872 |
Preparation of biodegradable microspheres useful as carriers for macromolecules
A method for preparing biodegradable microspheres having a three-dimensional network in which biologically active macromolecular agents are physically entrapped therein. The microsphere is able to...
|
|
|
4740372 |
Composition for treating psoriasis vulgaris and a method for its preparation
A composition for the treatment of psoriasis vulgaris, and a method for its preparation are described. The compound is made from the following ingredients: 6α,9α-difluoro-11β,...
|
|
|
4737363 |
Bacteroides nodosus vaccine
A vaccine for use in the prevention or treatment of foot-rot comprises an immunologically effective amount of at least one protease, particularly an extracellular serine protease, of Bacteroides...
|
|
|
4729893 |
Enteric encapsulation of ancrod for oral administration
Disclosed is a pharmaceutically effective agent and method of use, comprising ancrod which has been incubated with neuraminidase. The neuraminidase-treated ancrod (NTA) can be substituted for...
|
|
|
4696812 |
Thrombin preparations
Thrombin solutions can be rendered storage stable using stabilizing quantities of an anti-autolytic buffer in combination with low levels of saline and glycerol to prevent denaturation.
|
|
|
4687664 |
Method of inactivating reproducible pathogens
There is described a method of inactivating reproducible pathogens in preparations containing plasmatic enzymes and proenzymes, activated or non-activated coagulation factors, such as Factors II,...
|
|
|
4663164 |
Aqueous compositions for treating blood clotting factor inhibitors
Aqueous solutions of activated prothrombin complex concentrate are disclosed which have a F-VIII correctional activity of from about one to 35 units per ml. and an NAPT time of from about 27 to 70...
|
|
|
4645668 |
Method for the prevention and treatment of scars with enzymes
The method for preventing and for treating mammalian cicatrices such as keloids, acne scars, hypertrophic scars, wrinkles, cellulite and neoplastic fibrosis which comprises intra-dermal injection...
|
|
|
4642120 |
Repair of cartilage and bones
There are provided compositions for repairing defects of cartilage and bones. These are provided in gel form either as such, or embedded in natural or artificial bones. The gel comprises certain...
|
|
|
4637815 |
Irrigational hemostatic solution
A method and solution for enhancing coagulation. The solution comprises a pharmacologically active mixture of calcium chloride, epsilon-aminocaproic acid, protamine, thrombin and norepinephrine...
|
|
|
4620327 |
Process of adapting soluble bone protein for use in stimulating osteoinduction
A method for treating implants such as biodegradable masses, xenogenic bony implants, allografts and prosthetic devices with soluble bone protein to enhance or stimulate new cartilage and/or bone...
|
|
|
4575459 |
Toxoids of elastase of Pseudomonas aeruginosa origin
Provided herein are two kinds of toxoid of elastase of Pseudomonas aeruginosa origin, one of which is obtained by treating a purified elastase produced from Pseudomonas aeruginosa with a synthetic...
|
|
|
4568545 |
Thrombolytic agent
The invention discloses that the tissues of earthworms contain fibrinolytically or thrombolytically active ingredients which can be extracted and purified by a suitable sequence of extraction and...
|
|
|
4562071 |
Method of treating diabetic nephropathy
A therapeutic agent for the treatment of diabetic nephropathy is disclosed which contains elastase as active ingredient.
|
|
|
4559322 |
Non-absorbable compounds of mucolytic activity, the process for their preparation, and therapeutic compositions which contain them as active principle
Macromolecular compounds of mucolytic activity, non-absorbable by tissues, free from side-effects, compatible with antibiotics, and constituted by carbohydrates as their basic structure, to which...
|
|
|
4512973 |
Method for overcoming trypsin inhibition
The invention is directed to treating soy based foods with an effective amount of starfish trypsin 1 (DIT 1 ) to inactivate soybean trypsin inhibitor (STI). Also contemplated are the oral...
|
|
|
4508707 |
Hair tonic composition
A hair tonic composition comprising a gibberellin and an optional proteolytic enzyme as effective ingredients.
|
|
|
4507283 |
Pharmacologically active compounds
A derivative of streptokinase-human plasminogen activator complex, in which the active catalytic site essential for fibrinolytic activity is blocked by a 2- or 4-aminobenzoyl group, is useful in...
|
|
|
4505893 |
Purified plasminogen activator, process for its production and thrombolytic composition containing it
A plasminogen activator obtained from a tissue cultured liquor of human normal tissue derived cells, e.g., human embryonic derived cells, human placenta derived cells etc., and having the following...
|
|
|
4500514 |
Process for preparing a heat-stable aqueous solution of human urine kallikrein and product prepared
Human urine kallikrein dissolved in water is made heat-stable by the addition of a citric acid salt such as sodium citrate, so that an aqueous solution containing the kallikrein and the citric acid...
|
|
|
4485095 |
Pronase used for the treatment of diseases of the liver and kidneys in humans and animals
Diseases of the liver and kidneys in humans and animals may be prevented and treated by administering a therapeutically effective amount of a member selected from the group consisting of one or...
|
|
|
4479938 |
Therapeutic composition containing factor VIIa
Patients having a clotting factor defect can be successfully treated by the administration of a composition containing effective hemostatic amounts of factor VIIa. Preferably, the factor VIIa is...
|
|
|
4459288 |
Therapeutic blood clotting factor compositions and their use
Compositions including, in units/ml, factor VIII correctional activity, about from 2-35; prothrombin, about from 1-10; thrombin, less than about 0.003; factor VII, about from 37-190; factor VIIa,...
|
|
|
4456591 |
Therapeutic method for activating factor VII
Patients having a clotting factor defect can be successfully treated by the administration of a composition containing effective hemostatic amounts of factor VIIa. Preferably, the factor VIIa is...
|
|
|
4447416 |
Plasma protein concentrates of reduced thrombogenicity and their use in clinical replacement therapy
Plasma concentrates of vitamin-K dependent clotting factors of reduced thrombogenic potential useful for clinical replacement therapy in deficiency diseases of these clotting factors are provided....
|
|
|
4446129 |
Method for treatment of arthrosis deformans with elastase
A method is disclosed for treating a subject suffering from arthrosis deformans which comprises administering to said subject a therapeutically effective amount of a composition comprising elastase...
|
|
|
4440749 |
Preventive and treating agent for blood lipids abnormality and/or arteriosclerosis
A preventive and treating agent for blood lipids abnormally and/or arteriosclerosis comprises a proteolytic enzyme as an effective ingredient.
|
|
|
4397951 |
Elastase-containing composition permitting elastase to be absorbed in increased amount
An elastase-containing composition containing 0.5 to 50 parts by weight of sucrose fatty acid ester per part by weight of pure elastase, which composition permits elastase, useful as medicine for...
|
|
|
4390630 |
Hementin--a fibrinolytic agent
Novel fibrinolytic factors obtained from the salivary glands of Haementeria ghilianii. Proteins having molecular weights under about 100,000 are isolated from the salivary glands of H. ghilianii....
|
|
|
4382083 |
Therapeutic method for treating blood-clotting defects with factor VIIa
Patients having a clotting factor defect can be successfully treated by the administration of a composition containing effective hemostatic amounts of factor VIIa. Preferably, the factor VIIa is...
|
|
|
4357321 |
Method and composition for treating clotting factor inhibitors
A composition comprising about from 37 to 190 units of factor VII/ml and about from 25 to 80 units of factor VIIa/ml is administered to patients in the treatment of clotting factor inhibitors. The...
|
|
|
4337244 |
Enzyme derivatives for use in the treatment of venous thrombosis
Prophylactic or therapeutic method for the treatment of venous thrombosis by administering preferably intravenously to a human in need thereof a pharmaceutically acceptable carrier and an in vivo...
|
|
|
4315002 |
Solid pharmaceutical or diagnostic agent containing dextran and its preparation
A process for the preparation of a solid pharmaceutical or diagnostic composition in which the active substance and dextran are dissolved in water, the solution is placed in a mold and is...
|
|
|
4305926 |
Immobilization of Streptokinase
The invention comprises the construction of an implantable device consisting of a clot lysing inhibitor immobilized onto a biocompatible polymer, and the method of regulation of blood clotting...
|
|
|
4287180 |
Method for treating blood clotting factor inhibitors
Compositions including, in units/ml, factor VIII correctional activity, about from 2-35; prothrombin, about from 1-10; thrombin, less than about 0.003; factor VII, about from 37-190; factor VIIa,...
|
|
|
4276281 |
Burn treatment
Eschar is removed from mammalian skin burns by application of elastase to promote healing of the burned area by hastening the removal of the burn eschar. The elastase solution preferably comprises...
|
|
|
4273873 |
Preparation of antithrombogenic polymeric materials
Antithrombogenic polymeric materials are prepared by bonding a synthetic fibrinolytic compound or a combination of a synthetic fibrinolytic compound and a fibrinolytic enzyme to a polymeric...
|
|
|
4265233 |
Material for wound healing
A wound healing material having blood coagulation Factor XIII fixed thereto. This material promotes the formation of stabilized fibrin at a wound site and is effective for a long period of time,...
|
|
|
4242219 |
Novel enzyme particles and their preparation
A novel process for preparing non-dusting, enzyme-containing particles, e.g. for introduction into washing compositions, comprising homogeneously mixing an amount of an enzyme in dry or...
|
|
|
4229540 |
Hydrolase purified from human plasma
A previously undescribed hydrolytic enzyme has been successfully isolated from human plasma and purified to homogeneity. The enzyme has a molecular weight of about 70,000 daltons, has a Km for the...
|
|
|
4224179 |
Process for the preparation of liposomes in aqueous solution
A process for the preparation of a solution or suspension of liposomes in an aqueous medium comprising the steps of dispersing a first aqueous liquid in an essentially water-insoluble solvent in...
|
|
|
4191176 |
Intralenticular cataract surgery
An enzymatic intralenticular cataract treatment for removal of nuclear cortical and subcapsular regions of the cataractous lens through enzymatic digestion thereof which comprises introduction of a...
|
|
|
4178368 |
Method for the treatment of thromboembolism
A method for the treatment of thromboembolisms in a patient, said method consisting essentially of intravenously administering to said patient an effective amount of a complex formed between...
|